A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Trial Profile

A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Carotuximab (Primary)
  • Indications Choriocarcinoma; Gestational trophoblastic disease
  • Focus Therapeutic Use
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 11 May 2016 This trial is expected to initiate in the second half of 2016, according to a TRACON Pharmaceuticals media release.
    • 12 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top